Phase II evaluation of chlorozotocin in patients with malignant melanoma.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D009362:Neoplasm Metastasis; D010976:Platelet Count / Q000187:drug effects; D011336:Probability; D013311:Streptozocin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
C007028:chlorozotocin; D013311:Streptozocin